Home > Full Text Reviews > Effectiveness and Safety of... > Forest Plots of Meta-analysis of...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Talati R, Scholle JM, Phung OJ, et al. Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Dec. (Comparative Effectiveness Reviews, No. 40.)

Appendix JForest Plots of Meta-analysis of Efficacy and Safety Endpoints

Figure J-1. Composite forest plot of meta-analysis of mortality in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-2. Composite forest plot of meta-analysis of mortality in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-3. Composite forest plot of meta-analysis of mortality in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-4. Composite forest plot of meta-analysis of time to first seizure in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-5. Composite forest plot of meta-analysis of time to first seizure in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-6. Composite forest plot of meta-analysis of time to first seizure in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-7. Composite forest plot of meta-analysis of seizure occurrence in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-8. Composite forest plot of meta-analysis of seizure frequency in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-9. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-10. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-11. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with controlled or sustained release carbamazepine in controlled clinical trials

Figure J-12. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-13. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-14. Composite forest plot of meta-analysis of overall withdrawal in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-15. Composite forest plot of meta-analysis of withdrawals for any reason in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-16. Composite forest plot of meta-analysis of withdrawal due to lack of efficacy in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-17. Composite forest plot of meta-analysis of withdrawal due to lack of efficacy in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-18. Composite forest plot of meta-analysis of withdrawal due to lack of efficacy in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-19. Composite forest plot of meta-analysis of withdrawal due to lack of efficacy in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-20. Composite forest plot of withdrawal due to lack of efficacy in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-21. Composite forest plot of meta-analysis of withdrawals due to lack of efficacy in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-22. Composite forest plot of meta-analysis of twelve-month seizure remission in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-23. Composite forest plot of meta-analysis of 24-month seizure remission in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-24. Composite forest plot of meta-analysis of 12-month seizure remission in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-25. Composite forest plot of meta-analysis of 24-month seizure remission in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-26. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-27. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-28. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with controlled or sustained release carbamazepine in controlled clinical trials

Figure J-29. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-30. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-31. Composite forest plot of meta-analysis of seizure freedom for study duration in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-32. Composite forest plot of meta-analysis of maximum concentration (Cmax) in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-33. Composite forest plot of meta-analysis of minimum concentration (Cmin) in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-34. Composite forest plot of meta-analysis of steady-state concentration (Css) in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-35. Composite forest plot of meta-analysis of time to maximum concentration (Tmax) in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-36. Composite forest plot of meta-analysis of area under the curve (AUC) in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-37. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-38. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-39. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with controlled or sustained release carbamazepine in controlled clinical trials

Figure J-40. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-41. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-42. Composite forest plot of meta-analysis of withdrawal due to adverse events in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-43. Composite forest plot of meta-analysis of withdrawals due to adverse events in patients with epilepsy taking generic antiepileptic drugs compared with the corresponding innovator antiepileptic drug

Figure J-44. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-45. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-46. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with controlled or sustained release carbamazepine in controlled clinical trials

Figure J-47. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-48. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-49. Composite forest plot of meta-analysis of headache in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-50. Composite forest plot of meta-analysis of fatigue in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-51. Composite forest plot of meta-analysis of fatigue in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-52. Composite forest plot of meta-analysis of somnolence in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-53. Composite forest plot of meta-analysis of somnolence in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-54. Composite forest plot of meta-analysis of somnolence in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-55. Composite forest plot of meta-analysis of somnolence in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-56. Composite forest plot of meta-analysis of somnolence in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-57. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-58. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-59. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with controlled or sustained-release carbamazepine in controlled clinical trials

Figure J-60. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-61. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-62. Composite forest plot of meta-analysis of dizziness in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-63. Composite forest plot of meta-analysis of nausea in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-64. Composite forest plot of meta-analysis of nausea in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-65. Composite forest plot of meta-analysis of nausea in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-66. Composite forest plot of meta-analysis of vomiting in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-67. Composite forest plot of meta-analysis of vomiting in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-68. Composite forest plot of meta-analysis of vomiting in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-69. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-70. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in observational studies

Figure J-71. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with controlled- or sustained-release carbamazepine in controlled clinical trials

Figure J-72. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with phenytoin in controlled clinical trials

Figure J-73. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Figure J-74. Composite forest plot of meta-analysis of skin rash in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in observational studies

Figure J-75. Composite forest plot of meta-analysis of alopecia in patients with epilepsy taking newer antiepileptic drugs compared with carbamazepine in controlled clinical trials

Figure J-76. Composite forest plot of meta-analysis of gum hyperplasia in patients with epilepsy taking oxcarbazepine compared with phenytoin in controlled clinical trials

Figure J-77. Composite forest plot of meta-analysis of alopecia in patients with epilepsy taking newer antiepileptic drugs compared with valproic acid in controlled clinical trials

Cover of Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy
Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy [Internet].
Comparative Effectiveness Reviews, No. 40.
Talati R, Scholle JM, Phung OJ, et al.

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...